Menopause Treatment Market Sets Sights on US$ 22.9 Billion by 2032 | Future Market Insights,Inc.

The global menopause treatment market is expected to be valued at approximately US$ 13.3 billion in 2022, according to Future Market Insights’ most recent industry analysis. The market is expected to grow at a compound annual growth rate (CAGR) of nearly 5.5% over the course of the forecast period, reaching an estimated valuation of US$ 22.9 billion in 2032.

Hormone therapy comes with side effects due to the medication prescribed such as Tibolone, progestin, and estrogen, which is part of the therapy. Women experience vaginal bleeding, weight gain, breast tenderness, endometrial hyperplasia, and others, which are creating market scope for manufacturers to improve drug formulations that can address all these problems at once.

Bone fracture is also prevalent and relative cases of osteoporosis are also observed in women in their menopause. Menopause is also considered the common reason for osteoporosis as it has a direct relationship with the lack of estrogen. Women are at a high risk of fractures

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-15766

Rising investment in research and development and healthcare settings to develop novel therapy and medications putting emphasis on low-cost product development and lesser side effects are expected to propel the menopause treatment market growth during the forecast period.

Moreover, many startups are focusing on fundraising to support different programs. More tech-enabled startups trying to convince investors to fund women’s digital health.

Key Takeaways:

• Hormone therapy is the leading segment by product, and holds approximately 7% market value share in 2021, due to higher adoption and easier adoption of availability of medications that are used in hormone therapy.
• By route of administration, numerous studies demonstrate that women are substantially better protected against cardiovascular issues, with both heart attacks and strokes occurring at significantly lower rates when oral medications are prescribed. Hence, oral route of administration holds a market share of 0% in 2021.
• By distribution channel, retail sales are leading in the global menopause treatment market, and are expected to continue to do so with a projected CAGR of 6% during the forecasted years. Retail sales include retail pharmacies, drug stores, supermarkets, and hypermarkets, which are easily accessible and offer services like home delivery, making it the most lucrative among others.
• South Asia held the largest market share in the global menopause treatment market and estimated to grow at a CAGR of close to 6% due to the presence of a prestigious society and institutes that are educating and creating awareness among the population.

Unlock exclusive insights with our expert analysts:
https://www.futuremarketinsights.com/ask-question/rep-gb-15766

“Government campaigns creating awareness on women’s health and menopause is set to propel the sales of menopause treatment products across the globe,” says an analyst of Future Market Insights.

Market Competition

The market for menopause treatment is fragmented with well-established players, local and new entrants within the market sphere. Key players have initiated product launches with additional patient requirements addressing major issues related to side effects, attained regulatory approvals, and increased their manufacturing facilities.

• Theramex and Endoceutics expanded their initial contract in February 2022 to include the sale of Intrarosa® (prasterone) in Australia.
• In 2018, Glenmark Pharmaceuticals received the final approval from the US health regulator for a generic version of Nordisk Inc.’s VAGIFEM, for menopause symptoms.

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the menopause treatment market in its latest study, presenting a historical demand assessment of 2017 – 2021 and projections for 2022 – 2032. The global menopause treatment market is segmented in detail to cover every aspect of the market and presents a complete market intelligence approach to the reader.

The research study is based on product– (hormone therapy [combination, Tibolone, progestin-only medicines, and estrogen-only medicines] and non-hormonal therapy [gabapentinoids, serotonin-norepinephrine reuptake inhibitors (SNRI), selective serotonin reuptake inhibitors (SSRI), others]), route of administration (topical, injectable, and oral), and distribution channel (institutional sales [hospitals and specialty clinics], retail sales [retail pharmacies, drug stores, supermarkets/ hypermarkets, and online sales), across seven key regions of the world.

Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-15766

Key Segments :

By Product:

• Hormone Therapy
  • Combination
  • Tibolone
  • Progestin-Only Medicines
  • Estrogen-Only Medicines
• Non-Hormonal Therapy
  • Gabapentinoids
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)
  • Selective Serotonin Reuptake Inhibitors (SSRI)
  • Others

By Route of Administration:

• Topical
• Injectable
• Oral

By Distribution Channel:

• Institutional Sales
  • Hospitals
  • Specialty Clinics
• Retail Sales
  • Retail Pharmacies
  • Drug Stores
  • Supermarkets/ Hypermarkets
• Online Sales

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube